BBA
CRNX icon

Baker Bros. Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Baker Bros. Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.4M Buy
2,351,465
+702,596
+43% +$31.4M 0.49% 26
2025
Q4 		$76.8M Buy
1,648,869
+1,368,869
+489% +$60.9M 0.45% 31
2025
Q3 		$11.7M Hold
280,000
– – 0.08% 63
2025
Q2 		$8.05M Buy
+280,000
New +$8.65M 0.08% 57
2024
Q4 		– Sell
-103,927
Closed -$5.31M – 99
2024
Q3 		$5.31M Hold
103,927
– – 0.06% 66
2024
Q2 		$4.65M Buy
+103,927
New +$4.8M 0.06% 68
2022
Q4 		– Sell
-735,716
Closed -$14.4M – 117
2022
Q3 		$14.4M Sell
735,716
-91,764
-11% -$1.87M 0.09% 55
2022
Q2 		$15.4M Hold
827,480
– – 0.09% 56
2022
Q1 		$18.2M Hold
827,480
– – 0.1% 56
2021
Q4 		$23.5M Sell
827,480
-93,176
-10% -$2.3M 0.11% 53
2021
Q3 		$19.4M Hold
920,656
– – 0.09% 63
2021
Q2 		$17.4M Buy
920,656
+304,136
+49% +$5.34M 0.08% 65
2021
Q1 		$9.42M Hold
616,520
– – 0.04% 78
2020
Q4 		$8.7M Buy
616,520
+314,200
+104% +$4.38M 0.03% 78
2020
Q3 		$4.74M Sell
302,320
-15,537
-5% -$238K 0.02% 82
2020
Q2 		$5.57M Buy
317,857
+142,857
+82% +$2.44M 0.02% 78
2020
Q1 		$2.57M Hold
175,000
– – 0.02% 83
2019
Q4 		$4.39M Hold
175,000
– – 0.02% 74
2019
Q3 		$2.63M Buy
175,000
+42,015
+32% +$817K 0.02% 83
2019
Q2 		$3.33M Buy
132,985
+1,735
+1% +$43K 0.02% 71
2019
Q1 		$2.99M Hold
131,250
– – 0.02% 71
2018
Q4 		$3.94M Hold
131,250
– – 0.03% 59
2018
Q3 		$3.76M Buy
+131,250
New +$3.9M 0.02% 77

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Baker Bros. Advisors's CRNX Position: Q1 2026 in Review

Baker Bros. Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 43% in Q1 2026, buying an estimated $31.4M and bringing the position to 2,351,465 shares worth $85.4M. The position accounts for 0.49% of the portfolio, ranked #26.

Baker Bros. Advisors first reported a position in CRNX in Q3 2018 and has held it in 23 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Baker Bros. Advisors held 2,351,465 shares of Crinetics Pharmaceuticals worth $85.4M as of Q1 2026.
  • Baker Bros. Advisors bought 702,596 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $31.4M.
  • Crinetics Pharmaceuticals made up 0.49% of Baker Bros. Advisors's portfolio in Q1 2026, its #26 holding.
  • Baker Bros. Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.